Business Wire

FPT-CORPORATION

16.4.2024 08:23:31 CEST | Business Wire | Press release

Share
FPT Commits to Sustainable Development, Aligning with ESG Standards

As part of its ongoing commitment to the highest standards of sustainable development, FPT Corporation (FPT) has published its ESG report and prioritized ESG as a key aspect of its 2024 development strategy. The report highlights FPT’s achievement of 87% positive employee feedback, certified by Great Place to Work® - a significantly higher rating than a typical global company’s average of 53%. The Corporation is also certified among Vietnam's Top 10 Best Large-Scale Workplaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415745348/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Happy Run race is one of FPT’s social responsibility activities (Photo: Business Wire)

“In 2023, I described FPT as a joyful sanctuary. I delineated the concept wherein FPT assumed the role of building a happier future for shareholders, customers, and employees. This depiction has begun to manifest itself into reality,” said FPT Chairman Dr. Truong Gia Binh.

FPT’s ESG commitment is reflected in four key areas: Work Environment, Environmental Sustainability, Social Responsibility, and Excellent Governance, with actions taking references from Global Reporting Initiative (GRI) Standards and 17 Sustainable Development Goals of the United Nations.

Building on the core values of "Respect - Innovation - Cohesion - Equality - Exemplarity - Lucidity," FPT is committed to creating a happy, diverse, and inclusive workplace. The Corporation has employees from 73 nationalities, with women representing 37.4% of the total workforce and 36.1% of managerial roles.

In 2023, the number of foreign employees at FPT increased by 67% year-on-year to 2,925, including senior-level members from such companies as Airbus, SCSK, Tata Consultancy Services, and HCL. FPT also recorded a decade-low turnover rate of 10.3% and a 13.6% increase in the total workforce compared to 2022. “We prioritize building a cohesive, family-like atmosphere where leaders and employees regard one another as family. In times of adversity, we stand together and never leave anyone behind,” FPT Chairman Dr. Truong Gia Binh added.

Social responsibility forms an integral part of FPT's culture. In 2023, FPT donated VND 205.2 billion (approximately $8.2 million) to social responsibility activities, benefiting over 83,753 people in Vietnam. The company's first global Happy Run race attracted 191,000 participants, raising VND 3.6 billion (approximately $145,000) to build schools in remote areas. Hope School - FPT’s initiative to support children orphaned by COVID-19 - has continued to ensure a safe and comprehensive learning environment for 230 students from 41 provinces, with a new construction set to be completed in 2024.

The Corporation also demonstrates its strong commitment to environmental conservation and the ambitious goal of becoming the pioneering company in Vietnam to achieve Net Zero emissions by 2040. FPT has been applying various measures to minimize environmental impact by reducing energy consumption and greenhouse gas emissions, such as monitoring 100% of energy usage data and replacing 100% of office waste bags with recyclable materials, while ensuring all employees receive annual training on environmental protection policy.

Regarding corporate governance, FPT pledges to build and maintain a governance framework including charter, regulations, process handbooks, and regulatory documents across the Corporation to ensure a professional, effective and disciplined governance system from the Corporation to its subsidiaries.

Vertical functional management and centralized data management serve as the "backbone" of FPT's efforts to optimize its management and operations, as well as fostering sustainable growth. The Corporation also conducted internal digital transformation projects, with 42 being implemented in 2023 to ensure cost savings, optimize operations, and improve experience for both employees and customers.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com.vn/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415745348/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye